Jellagen
Jellagen is a UK medtech company that manufactures medical-grade Collagen Type 0, a jellyfish-derived fibrillar collagen biomaterial, supplying advanced wound care, orthopaedic, 3D bioprinting, and regenerative medicine applications to enterprise healthcare and medical device customers worldwide.
- Company typePrivate
- Founded2015
- HeadquartersPembroke Dock, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jellagen does
Jellagen is a privately held UK medtech company founded in 2013 and incorporated in 2015, headquartered at a 10,000 square-foot ISO 13485:2016 certified R&D, manufacturing, and commercial facility in Cardiff, Wales. The company develops and manufactures medical-grade Collagen Type 0 (Type Zero), a fibrillar collagen extracted from the jellyfish Rhizostoma pulmo via a proprietary process that preserves the triple helix structure and achieves batch-to-batch amino acid consistency of approximately 0.2%. Designated "Type 0" because it predates mammalian collagens by approximately 600 million years, the product is positioned as a non-mammalian, non-immunogenic, pro-angiogenic alternative to bovine, porcine, and rodent collagens, free from prion and disease transmission risks.
The product platform spans medical device formats (micronized powder wound dressings, scaffolds, films, sponges, hydrogels), research products (Collagen Type 0 BioINK for 3D bioprinting co-developed with Copner Biotech), and the JellaGel sub-brand for extracellular matrix applications, targeting advanced wound care, orthopaedics, medical device manufacturers, research and life sciences, and specialist medical applications. The company has built an evidence base through 15+ peer-reviewed publications and collaborations with Mayo Clinic, NPL, Cellaria, and Copner Biotech, and holds a US patent for combined Nitric Oxide and Collagen delivery.
Jellagen monetizes through direct B2B sales to enterprise healthcare and medical device customers under a quote-based pricing model, licensing and co-development revenue with strategic partners, and — since February 2026 — exclusive North American distribution rights held by Royal Biologics, with the partner's CEO joining Jellagen's board. The go-to-market combines enterprise field sales led by CEO Thomas-Paul Descamps, an international distributor network, and content-driven marketing through scientific publications, whitepapers, and industry events. The company is pre-commercial or early-revenue, with cumulative funding of approximately £18M+ across multiple rounds since 2016 and a small team of 1–10 employees.
Jellagen firmographics
Firmographics- Name
- Jellagen
- Legal name
- Jellagen Pty Ltd
- Website
- https://jellagen.co.uk
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Jellagen is a UK medtech company that manufactures medical-grade Collagen Type 0, a jellyfish-derived fibrillar collagen biomaterial, supplying advanced wound care, orthopaedic, 3D bioprinting, and regenerative medicine applications to enterprise healthcare and medical device customers worldwide.
- Ownership category
- akta.pro rank
Jellagen industry classification
Industry- Product category
- Medical Biomaterials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Marine & Aquatic Protein Ingredients (Fish Protein, Shellfish Protein, Fish Collagen) (AFAJAHAD)
- akta.pro secondary industries
- Gelatin & Animal-Derived Hydrocolloids (Gelatin, Collagen, Isinglass) (AFAJAMAG), Animal-Derived Protein Ingredients (Egg, Collagen/Gelatin, Blood/Plasma Proteins) (AFAJAHAB), Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ)
Keywords
Where Jellagen is headquartered
LocationHeadquarters
- HQ city
- Pembroke Dock
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Jellagen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical-Grade Collagen Type 0 Product Sales: Jellagen manufactures and sells medical-grade Collagen Type 0 biomaterials in various formulations (liquid, powder, films, sponges, hydrogels, bioinks) to healthcare providers, medical device companies, and research institutions for tissue engineering, wound healing, and regenerative medicine applications.
- Licensing and Co-Development Revenue: Royal Biologics partnership includes exclusive North American rights to Collagen Type Zero products. Jellagen co-develops wound matrices and implantable regenerative solutions, generating revenue through licensing fees, milestone payments, and product royalties from commercial partners.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Jellagen product offering
Product offeringCore offering
Jellagen manufactures and sells medical-grade Collagen Type 0, a fibrillar collagen biomaterial derived from the jellyfish Rhizostoma pulmo. The proprietary extraction process maintains the characteristic triple helix structure, producing non-immunogenic, non-mammalian collagen formulated as liquids, powders, films, sponges, hydrogels, and bioinks for wound care, tissue engineering, and regenerative medicine applications.
Product overview
Jellagen operates as a single unified product platform centered on Collagen Type 0, a jellyfish-derived collagen biomaterial. The core product serves as the foundation for multiple product lines including medical devices (Micronized Collagen Type 0 Powder for wound care, wound dressings), research products (BioINK for 3D bioprinting, scaffolds for bone/orthopaedic applications), and the JellaGel™ sub-brand for extracellular matrix applications. All products derive from the company's proprietary Collagen Type 0 platform extracted from Rhizostoma pulmo jellyfish, offering a non-mammalian alternative to traditional collagen sources for tissue engineering and regenerative medicine.
Differentiator
Problem solved
Functional benefit
Brands
- JellaGel: Extracellular matrix product derived from jellyfish Collagen Type 0 for medical applications and biological research.
Products and services
- Collagen Type 0 A chemically ancient, medical-grade fibrillar collagen derived from jellyfish (Rhizostoma pulmo) for tissue engineering and regenerative medicine. Non-mammalian, non-immunogenic, pro-angiogenic, and pro-tissue neogenic; free from disease and prion risks associated with mammalian collagen sources. Available in multiple formulations.
- Micronized Collagen Type 0 Powder A patented, micronized powder form of Collagen Type 0 intended to be applied as powder or paste for wound care applications. Provides intimate contact with all areas of the wound bed including irregular, tunnelled, or undermined wounds. Designed for advanced wound care providers treating chronic wounds, diabetic ulcers, and non-healing wounds.
- JellaGel Extracellular matrix type 0 product derived from jellyfish collagen, representing Jellagen's versatile product pipeline for medical applications and biological research, including tissue engineering. Featured in publication with NPL and established as a branded product line.
- Collagen Type 0 BioINK A novel Collagen Type 0 bio-ink formulation for 3D bioprinting applications, developed with Copner Biotech's GRAPE-S1 technology platform. Formulated with rheological properties enabling creation of complex 3D tissue architectures for research and tissue engineering applications.
- Collagen Type 0 Scaffolds Collagen scaffolds for bone regeneration and orthopaedic applications, providing biocompatibility and adhesive properties for cell culture and bone tissue engineering applications. Used by medical device companies and orthopaedic researchers.
- Collagen Type 0 Wound Dressing
Quantifiable outcome
- >45% bone growth in cranial wound model with Collagen Type 0 vs. 9% in untreated control group
- +5 more outcomes
Companies that use Jellagen
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles4 records
Jellagen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Jellagen partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered flagship and core.
- Royal BiologicsflagshipRoyal Biologics announced a strategic partnership and investment with UK-based Jellagen to commercialize Collagen Type Zero in North America. Royal Biologics gains exclusive North American rights and will co-develop wound matrices and implantable regenerative solutions. Salvatore Leo, CEO of Royal Biologics, joins Jellagen's board as strategic commercialization lead. This partnership positions Royal Biologics as the first U.S. company to introduce jellyfish-derived collagen, creating a category-defining product line in biologics.
- National Physical Laboratory (NPL)coreJellagen and NPL collaborated on research published in Materials Today Bio demonstrating further jellyfish Collagen Type 0 as the foundation for a range of new medical applications and to support new biological research. The collaboration established Collagen Type 0 and JellaGel as a versatile product pipeline.
- Copner Biotech LtdcoreCopner Biotech (Lead) and Jellagen were awarded £431,142 Innovate UK funding to develop a next-generation 3D Inkjet bioprinting platform with a novel Collagen Type 0 BioINK formulation. The 19-month project is part of Copner Biotech's roadmap to establish a bioprinting centre of excellence in Wales, UK.
- Copner Biotech LtdcoreJellagen and Copner Biotech completed a world-first SMART Cymru-funded project developing a next-generation bioprinting system and bio-ink using Jellagen's jellyfish-derived Collagen Type 0 combined with Copner Biotech's GRAPE-S1 bioprinter. The project successfully demonstrated printing of structures <100 microns in diameter using Collagen Type 0 as a bioink platform.
- Cellaria Inc.coreJellagen partnered with Cellaria Inc. to offer a paradigm shift in collagen chemistry to develop next-generation models for cancer research. This partnership leverages Jellyfish Collagen Type 0 as a superior matrix for 3D cancer cell culture models.
- Mayo CliniccoreJellagen established development collaborations with Mayo Clinic in the US to investigate and corroborate findings on Collagen Type 0 for regenerative medicine applications. Mayo Clinic is featured as a collaborator logo on the company website.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Jellagen competitors and assessment
Company assessmentDirect peers
- Advanced BioMatrix: US-based specialist in collagen, hydrogel, and extracellular matrix products for 3D cell culture, tissue engineering, and research applications. Comparable niche player focused on collagen-based biomaterials for research and regenerative medicine, similar customer profile (academic researchers, biotech R&D).
- BICO (formerly Cellink): Swedish 3D bioprinting and biofabrication company providing bioinks, bioprinters, and tissue engineering solutions. Directly comparable on the bioink and 3D bioprinting side of Jellagen's Collagen Type 0 BioINK platform; both target researchers and pharma with cell culture and tissue model solutions.
- CollPlant Biotechnologies: Israel-based biotech producing recombinant human collagen (from tobacco plants) for regenerative medicine, wound healing, and 3D bioprinting. Closest direct peer to Jellagen: both develop non-mammalian collagen platforms targeting tissue engineering, wound care, and bioink applications with comparable regulatory and clinical pathways.
- Regenity Biosciences (formerly Collagen Solutions): UK-based medical-grade collagen specialist supplying biomaterials for tissue repair, regenerative medicine, and implantable devices. Directly comparable to Jellagen on product (medical-grade collagen), customer base (medical device OEMs), and regulatory pathway; both serve wound care, orthopedics, and cardiac applications.
Broad incumbents
- Rousselot (Darling Ingredients): Global leader in gelatin and collagen peptides for pharmaceutical, food, and biomedical applications. Comparable to Jellagen on collagen chemistry and biomedical applications but at vastly larger scale and broader portfolio; represents the established incumbent Jellagen must displace in medical-grade collagen supply.
- Organogenesis Holdings: US-listed regenerative medicine company specializing in advanced wound care (skin substitutes, amniotic membranes) and surgical biologics. Broad incumbent in Jellagen's primary addressable segment (advanced wound care); both compete for the same clinician formulary slots and CMS reimbursement.
- Gelita: German-headquartered global manufacturer of collagen peptides and gelatin for health, nutrition, and pharmaceutical/biomedical markets. Broad incumbent in the collagen/biomaterial space; comparable product chemistry (gelatin/collagen hydrolysates) but operates at commodity scale rather than Jellagen's specialty medical-grade positioning.
- MiMedx Group: US-listed regenerative medicine company focused on wound care, surgical recovery, and orthopedics using placental tissue allografts. Broad incumbent in the advanced wound care space where Jellagen's micronized collagen powder is positioned; competes for the same CMS-reimbursed wound care channels reshaped by the 2024 reimbursement reset.
- Croda International: UK-listed specialty chemicals company with significant life sciences and biomedical materials business including collagen-derived ingredients for wound care, dermal, and tissue engineering. Broad incumbent with comparable end-markets and customer overlap (medical device OEMs, pharma).
- Integra LifeSciences: US-listed medical technology company with leadership positions in regenerative tissue technologies (collagen-based wound care, dermal matrices, dural repair) and orthopedic implants. Broad incumbent; significant overlap with Jellagen on collagen biomaterials for wound care, orthopedics, and implantable regenerative solutions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Jellagen social profiles
Digital presenceJellagen compliance and trust
Trust signalCompliance1 record
Jellagen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jellagen leadership team
Management profileNumber of profiles
Profiles7 records
Jellagen funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jellagen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jellagen
What does Jellagen do?
Jellagen manufactures and sells medical-grade Collagen Type 0, a fibrillar collagen biomaterial derived from the jellyfish Rhizostoma pulmo. The proprietary extraction process maintains the characteristic triple helix structure, producing non-immunogenic, non-mammalian collagen formulated as liquids, powders, films, sponges, hydrogels, and bioinks for wound care, tissue engineering, and regenerative medicine applications.
Is Jellagen a public or private company?
Jellagen is a private company. It is classified as venture growth investor backed and is currently operating.
When was Jellagen founded?
Jellagen was founded in 2015. It employs 1 to 10 people.
Where is Jellagen based?
Jellagen is headquartered in Pembroke Dock, United Kingdom, in the Europe region.
How does Jellagen make money?
Two revenue lines are on record. Medical-Grade Collagen Type 0 Product Sales are the primary driver. The others are licensing and Co-Development Revenue.
Who are Jellagen's main competitors?
Direct peers on record are Advanced BioMatrix, BICO (formerly Cellink), CollPlant Biotechnologies and Regenity Biosciences (formerly Collagen Solutions). Broad incumbents are Rousselot (Darling Ingredients), Organogenesis Holdings, Gelita, MiMedx Group, Croda International and Integra LifeSciences.
Does Jellagen have an API?
No public API is recorded for Jellagen.
What industry is Jellagen in?
Jellagen's product category is Medical Biomaterials. Its primary akta.pro industry code is AFAJAHAD, Marine & Aquatic Protein Ingredients (Fish Protein, Shellfish Protein, Fish Collagen), with a secondary code of AFAJAMAG, Gelatin & Animal-Derived Hydrocolloids (Gelatin, Collagen, Isinglass). Its NAICS code is 325414 and its SIC code is 2836.